

Correction

Lapatinib and IGF-I signaling

In the article on lapatinib and IGF-I signaling in the February 2007 issue (1), Fig. 3 is incorrect. The corrected Fig. 3 and legend appears below. The statement that lapatinib induces expression of p27kip1 should be removed from the abstract (page 667), the Results section (page 669, 4th paragraph), and the legend for Fig. 3B.




Figure 3. Lapatinib inhibits EGFR and HER2 signaling in trastuzumab resistant cells. Parental, pool 2, clone 3, and clone 4 cells were treated with 1 $\mu\text{mol/L}$ lapatinib for 24 h. Immunoblotting (30 μg) was done (A) for phosphorylated and total HER2 and EGFR and (B) for the downstream signaling molecules, phosphorylated and total Akt, mitogen-activated protein kinase, and S6. Actin served as a loading control. Lapatinib inhibited EGFR and HER2 phosphorylation and blocked signaling pathway downstream of these receptors in parental and resistant cells.

Reference

1. Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. *Mol Cancer Ther* 2007;6:667–74.

Molecular Cancer Therapeutics

Lapatinib and IGF-I signaling

Mol Cancer Ther 2008;7:3654.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/7/11/3654.3>

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://mct.aacrjournals.org/content/7/11/3654.3.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://mct.aacrjournals.org/content/7/11/3654.3>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.